GLPG: מכפיל מחיר להכנסות Galapagos N.V.

Geopolitical instability and sanctions are hindering global clinical trials for new drugs, a trend reflected in the price action of Galapagos NV (GLPG). The EV/Revenue multiple clearly demonstrates the current market valuation, with the latest reading standing at 1.40. Business resilience is supported by the diversification of European plants, while the strategic focus is shifting toward decentralized CAR-T therapy production for oncology clinics.

To filter for fundamentally resilient assets, investors compare market capitalization against actual cash flows from sales. This ratio determines the cost per unit of revenue, which is critical for Galapagos NV (GLPG), as the company delegates production and research to contractors to reduce capital expenditures; consequently, the P/S trajectory allows for an objective assessment of the efficiency of this outsourcing model relative to the market price.